University of Kansas Cancer Center Post San Antonio Review

 

University of Kansas Cancer Center Post San Antonio Review
S

BC Predisposition Genes San Antonio Review: Who to Test? Should the Threshold of Detection of Pathogenic Variants Be Mandate or Offer Testing? What Genes to Include?

By University of Kansas Cancer Center Post San Antonio Review FEATURING Susan Domchek
By University of Kansas Cancer Center Post San Antonio Review FEATURING Susan Domchek
90 views
February 28, 2021
1 Comment
Login to view comments. Click here to Login
2021
14:39
University of Kansas Cancer Center Post San Antonio Review

What's New in HER2+ MBC Targeted Therapy: Efficacy Analysis of …

Feat. H. McArthur
16:19
University of Kansas Cancer Center Post San Antonio Review

2021 Changing Treatment Paradigms for HER2+ mBC: Expert Efficacy Ana…

Feat. H. McArthur
14:55
University of Kansas Cancer Center Post San Antonio Review

50 y/o Premenopausal Woman With T2N1mic BC: Would You Order Gene Exp…

Feat. P. Sharma, S. Tolaney, I. Mayer, Q. Khan, J. Balko
14:05
University of Kansas Cancer Center Post San Antonio Review

Challenging Cases of BC: What Should Be the Next Line of Therapy for…

Feat. P. Sharma, S. Tolaney, I. Mayer, Q. Khan, J. Balko
12:04
University of Kansas Cancer Center Post San Antonio Review

48 y/o PALB2 Mutation Carrier With T2N0 ER/PR+, HER2- BC: How to Cou…

Feat. P. Sharma, J. Klemp, H. McArthur, S. Domchek
08:29
University of Kansas Cancer Center Post San Antonio Review

42 y/o With cT2N Grade III TNBC: Does Inclusion of CPIs & Carbop…

Feat. P. Sharma, J. Klemp, H. McArthur, S. Domchek
07:56
University of Kansas Cancer Center Post San Antonio Review

Expert Discussion on Challenging BC Cases: What Treatment Option to …

Feat. P. Sharma, J. Klemp, H. McArthur, S. Domchek
19:16
University of Kansas Cancer Center Post San Antonio Review

BC Predisposition Genes San Antonio Review: Who to Test? Should the …

Feat. S. Domchek
17:29
University of Kansas Cancer Center Post San Antonio Review

SABCS Updates on HR+, HER2- MBC: What Is the Role of HDACi? Does Int…

Feat. S. Tolaney
07:53
University of Kansas Cancer Center Post San Antonio Review

SABCS Data on mTNBC: 1L Chemo + IO in PD-L1+ Disease, Sacituzumab Go…

Feat. S. Tolaney
21:41
University of Kansas Cancer Center Post San Antonio Review

Endocrine Resistance in BC: Mechanisms and Treatment Strategies

Feat. J. Balko
31:02
University of Kansas Cancer Center Post San Antonio Review

Genomic Signatures in Adjuvant Therapy of HR+ EBC: Should We Conside…

Feat. I. Mayer
27:20
University of Kansas Cancer Center Post San Antonio Review

Predictive & Prognostic Biomarkers in Neoadjuvant TNBC: How Valu…

Feat. A. Bardia